Edition:
United States

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

66.00CHF
15 Dec 2017
Change (% chg)

CHF-0.40 (-0.60%)
Prev Close
CHF66.40
Open
CHF66.25
Day's High
CHF66.30
Day's Low
CHF65.70
Volume
85,986
Avg. Vol
107,491
52-wk High
CHF68.25
52-wk Low
CHF52.05

Latest Key Developments (Source: Significant Developments)

BB Biotech Q3 net profit down at CHF 365 million
Friday, 20 Oct 2017 01:00am EDT 

Oct 20 (Reuters) - BB BIOTECH AG ::PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER.Q3 ‍NET PROFIT AMOUNTED TO CHF 365 MN VERSUS PROFIT OF CHF 392 MN REPORTED IN Q3 LAST YEAR​.  Full Article

BB Biotech H1 net result turns to profit of CHF 478 mln
Friday, 21 Jul 2017 01:00am EDT 

July 21 (Reuters) - BB BIOTECH AG ::‍CONSEQUENTLY, H1 2017 NET INCOME AMOUNTED TO CHF 478 MN, COMPARED TO A LOSS OF CHF 1 170 MN FOR H1 2016​.‍Q2 NET INCOME AMOUNTED TO CHF 103 MN, COMPARED TO CHF 36 MN FOR SAME PERIOD IN 2016​.  Full Article

BB Biotech posts Q1 net profit of 375 million Swiss francs
Friday, 21 Apr 2017 01:00am EDT 

April 21 (Reuters) - Bb Biotech Ag :Reports pleasing quarterly results.Earned a bottom-line profit of 375 million Swiss francs ($375.45 million) in Q1 of 2017 .For remainder of 2017, BB Biotech expects a series of late stage clinical trial read-outs and an increase in number of product approvals during 2017 compared to 2016.Expects US healthcare reform debate to simmer (discussion of Affordable Care Act continues in Congress).Drug pricing may remain a popular topic for presidential tweets, and more serious initiatives may be expected around "best-prices" and "value-based prices" during 2017 and beyond.Johnson & johnson's acquisition of actelion is expected to deliver significant cash for bb biotech in Q2.Will consider selective increases in undervalued portfolio positions and continue to add promising new smaller and mid-cap positions to its investment portfolio.  Full Article

BB Biotech FY operating income down at CHF 9.5 mln
Friday, 17 Feb 2017 01:08am EST 

BB Biotech AG :FY operating income 9.5 million Swiss francs ($9.52 million)versus 697.9 million Swiss francs year ago.  Full Article

BB Biotech proposes dividend of CHF 2.75 per share
Friday, 20 Jan 2017 01:00am EST 

BB Biotech AG : Portfolio performs well in in the volatile fourth quarter of 2016 . 5% dividend yield maintained - BB Biotech management is very confident about sector's prospects in 2017 . A proposed dividend of 2.75 Swiss francs ($2.74)per share . 2017 will bring an acceleration of important product approvals and milestone read-for industry and bb biotech's portfolio . Consolidated but not yet audited Q4 data for BB Biotech record a net loss of 24 mln Swiss francs versus last year's quarter gain of 511 mln Swiss francs .Consolidated but not yet audited full year 2016 data, showed a net loss of 802 mln Swiss francs versus a full year net profit of 653 mln Swiss francs for 2015..  Full Article

BB Biotech swings to prelim Q3 profit of CHF 392.1 mln
Tuesday, 11 Oct 2016 12:10pm EDT 

BB Biotech AG : BB Biotech AG with profit in the third quarter 2016 . Based on preliminary unaudited consolidated results, BB Biotech closed Q3 of 2016 with a profit of 392.1 million Swiss francs ($401.41 million)(575.4 million francs loss in corresponding period of previous year) .For nine months period ended September 30, 2016 BB Biotech reports a loss of 777.8 million Swiss francs (141.4 million francs profit in corresponding period of previous year).  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Tuesday, 27 Sep 2016 04:22pm EDT 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

BB Biotech Q2 net profit of CHF 36 mln
Friday, 22 Jul 2016 01:01am EDT 

BB Biotech AG : Expects a return to growth from its portfolio holdings in coming quarters and for FY 2016 as a whole . Q2 net profit of 36 million Swiss francs ($36.59 million) .Net result for first half was a negative 1170 million Swiss francs due to loss reported for Q1.  Full Article

BB Biotech swings to H1 net loss of CHF 1.17 bln
Monday, 11 Jul 2016 12:10pm EDT 

BB Biotech AG :Based on preliminary unaudited consolidated results, BB Biotech AG closed first half year of 2016 with a loss of 1.17 billion Swiss francs ($1.19 billion)(717 million Swiss francs profit in corresponding period of previous year)..  Full Article

BB Biotech proposes dividend of 14.50 Swiss francs per share
Friday, 19 Feb 2016 01:00am EST 

BB Biotech AG:Further significant increase in dividend of 25 pct to 14.50 Swiss francs per share, five-for-one share split proposed​ ‍.In its outlook for 2016, BB Biotech expects more announcements of regulatory approvals as well as strong pipeline newsflow from its portfolio companies​.  Full Article

BRIEF-BB Biotech Q3 net profit down at CHF 365 million

* PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER